Sekhar told CNBC-TV18, "Glenmark Pharma has been coming out of a setback on the R&D front but it is slowly and steadily seeing a recovery across all its regions and operations. It has got a strong pipeline and going forward there is a good probability that they can strike out; some very attractive outlays in license deals. So I am expecting around a 20-25% kind of upside in this stock atleast from a 6-9 month perspective, so clearly it is a good time to buy."
